Navios Maritime Acquisition Corporation Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2018
Revenue: $58.7 million for Q4 2018; $187.9 million for 2018 Market improvement; Baltic TD3C TCE: Q4 2018 was 2x Q4 […]
Victory Capital Names Michael Policarpo President, Chief Financial Officer And Chief Administrative Officer
CLEVELAND, Ohio, Feb. 06, 2019 (GLOBE NEWSWIRE) — Victory Capital Holdings, Inc. (NASDAQ: VCTR) (“Victory Capital” or “the Company”) today […]
Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan
REDWOOD CITY, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS) announces a multi-year, exclusive supply agreement with […]
KVH Industries’ COO to Speak at the Cowen and Company 40th Annual Aerospace/Defense Conference
MIDDLETOWN, R.I., Feb. 06, 2019 (GLOBE NEWSWIRE) — KVH Industries, Inc., (Nasdaq: KVHI), chief operating officer, Brent Bruun, will be […]
Malibu Boats, Inc. Announces Second Quarter Fiscal 2019 Results
LOUDON, Tenn., Feb. 06, 2019 (GLOBE NEWSWIRE) — Malibu Boats, Inc. (Nasdaq: MBUU) today announced its financial results for the […]
Victory Capital Reports Fourth Quarter 2018 Results
Fourth Quarter 2018 Highlights¹ Assets under management (“AUM”) of $52.8 billion Strong investment performance, with 57%, 68%, 74% and 88% […]
Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine
FDA agreement achieved on Phase 3 trial design, endpoints, and statistical approach Trial to enroll patients with a history of […]
BioCryst Strengthens Cash Position With Flexible $100 Million Debt Facility
—New loan facility increases to $50 million to further extend cash runway— —Additional $30 million available at company option following […]
InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa
Retrospective long-term results from phase IIa trial indicate sustained remission post IFX-1 treatment Baseline characteristics from ongoing phase IIb SHINE […]
IRADIMED CORPORATION Announces Fourth Quarter 2018 Financial Results
Reports fourth quarter 2018 revenue of $8.3 million Reports fourth quarter 2018 GAAP diluted EPS of $0.14 and non-GAAP diluted […]
